KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

被引：0
|
作者：
Galsky, M. [1 ]
Necchi, A. [2 ]
Shore, N. D. [3 ]
Witjes, F. [4 ]
Nam, K. [5 ]
Godwin, J. L. [5 ]
Frenkl, T. L. [5 ]
Plimack, E. R. [6 ]
机构：
[1] Mt Sinai Hosp, Icahn Sch Med, Tisch Canc Inst, New York, NY 10029 USA
[2] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
[3] Carolina Urol Res Ctr, Med Oncol, Myrtle Beach, SC USA
[4] Radboudumc, Urol, Nijmegen, Netherlands
[5] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[6] Fox Chase Canc Ctr, Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
989TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer
    Li, Roger
    Nocera, Luigi
    Rose, Kyle M.
    Raggi, Daniele
    Naidu, Shreyas
    Mercinelli, Chiara
    Cigliola, Antonio
    Tateo, Valentina
    Patane, Damiano
    Grass, G. Daniel
    Gilbert, Scott M.
    Sexton, Wade J.
    Bandini, Marco
    Moschini, Marco
    Briganti, Alberto
    Montorsi, Francesco
    Spiess, Philippe E.
    Necchi, Andrea
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 614 - 624
  • [32] Prognostic classification of muscle-invasive bladder cancer (MIBC) following radical cystectomy (RC) alone or with perioperative chemotherapy: Analysis of the US National Cancer Database (NCDB).
    Sonpavde, Guru
    Nelson, Rebecca A.
    Pond, Gregory Russell
    Nix, Jeffrey
    Chennamsetty, Avinash
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [33] Randomized phase 2 umbrella study of various neoadjuvant therapies for patients with muscle-invasive urothelial carcinoma of the bladder (MIBC) who are cisplatin-ineligible or refuse cisplatin therapy and undergoing radical cystectomy (Optimus).
    Necchi, Andrea
    Zakharia, Yousef
    Ghali, Nadeem
    Smith, Michael
    Hamer-Maansson, J. E.
    Lindley, Anouk
    Loriot, Yohann
    Meeks, Joshua J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [34] PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible.
    Grivas, Petros
    Van der Heijden, Michiel Simon
    Necchi, Andrea
    Siefker-Radtke, Arlene O.
    Cutuli, Hernan
    Qureshi, Anila H.
    Kreiser, Stephanie
    Hodari, Moana
    Ravimohan, Shruthi
    Zakharia, Yousef
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [35] The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy
    Murasawa, Hiromi
    Koie, Takuya
    Ohyama, Chikara
    Yamamoto, Hayato
    Imai, Atsushi
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Iwabuchi, Ikuya
    Ogasawara, Masaru
    Kawaguchi, Toshiaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (01) : 159 - 165
  • [36] Identifying high surgical risk in muscle-invasive bladder cancer (MIBC) patients undergoing radical cystectomy (RC)
    Marqueen, Kathryn E.
    Waingankar, Nikhil
    Sfakianos, John
    Mehrazin, Reza
    Niglio, Scot Anthony
    Audenet, Francois
    Jia, Rachel
    Mazumdar, Madhu
    Ferket, Bart
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [37] Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomy
    Pichler, Renate
    Fritz, Josef
    Mari, Andrea
    Cadenar, Anna
    von Deimling, Markus
    Marcq, Gautier
    del Giudice, Francesco
    Leonardo, Costantino
    Bologna, Eugenio
    Mori, Keiichiro
    Tahbaz, Rana
    De Santis, Maria
    Klatte, Tobias
    Erber, Barbara
    Lackner, Felizian
    Kronbichler, Andreas
    Seeber, Andreas
    Fisch, Margit
    Moschini, Marco
    Pradere, Benjamin
    Mertens, Laura S.
    ONCOLOGIST, 2024, 29 (11): : e1511 - e1522
  • [38] The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy
    Hiromi Murasawa
    Takuya Koie
    Chikara Ohyama
    Hayato Yamamoto
    Atsushi Imai
    Shingo Hatakeyama
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Ikuya Iwabuchi
    Masaru Ogasawara
    Toshiaki Kawaguchi
    International Journal of Clinical Oncology, 2017, 22 : 159 - 165
  • [39] A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer
    Freiha, F
    Reese, J
    Torti, FM
    JOURNAL OF UROLOGY, 1996, 155 (02): : 495 - 499
  • [40] Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC)
    Balar, Arjun Vasant
    Iyer, Gopa
    Apolo, Andrea Borghese
    Regazzi, Ashley Marie
    Garcia-Grossman, Ilana Rebecca
    Pendse, Deepa
    Ostrovnaya, Irina
    Chou, Joanne F.
    Bochner, Bernard
    Dalbagni, Guido
    Herr, Harry W.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345